The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognosis of locoregional recurrence after early breast cancer with immediate breast reconstruction.
 
Hirohito Seki
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Pfizer
 
AKiko Ogiya
No Relationships to Disclose
 
Naomi Nagura
No Relationships to Disclose
 
Ayaka Koike-Shimo
No Relationships to Disclose
 
Kazutaka Narui
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Lilly Japan
 
Shinsuke Sasada
No Relationships to Disclose
 
Makoto Ishitobi
No Relationships to Disclose
 
Hiroko Nogi
No Relationships to Disclose
 
Naoto Kondo
No Relationships to Disclose
 
Teruhisa Sakurai
No Relationships to Disclose
 
Chikako Yamauchi
No Relationships to Disclose
 
Hiroki Mori
Speakers' Bureau - Abbvie.co.jp; Biomaster; PRSS.Japan
 
Miho Saiga
No Relationships to Disclose
 
Naoki Niikura
No Relationships to Disclose
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)